As ADCs continue to redefine the standard of care in oncology, breakthrough clinical readouts, expanding approvals in earlier treatment settings, and a wave of landmark dealmaking have cemented ADCs as one of biopharma's most sought-after areas of investment. From Novartis' billion-dollar technology partnership with Myricx Bio to Gilead's acquisition of Tubulis, the industry's leading players are racing to secure differentiated linker-payload technologies, unlock novel targets, and develop the next generation of transformative ADC therapies for patients with hard-to-treat cancers. Returning as Europe's largest and longest-standing annual meeting for the ADC community, the 17th World ADC London returns in March as the definitive week to benchmark against industry leaders, validate internal strategies, forge strategic partnerships, and shape the future of ADC development. Bringing together 700+ senior leaders from biopharma, biotech, academia, clinical research, investment, and solution providers, this is where the brightest minds and most innovative companies converge to accelerate progress across the field. Featuring five streams of end-to-end content spanning discovery, preclinical and translational development, clinical lessons, process and analytical development, and manufacturing and supply chain, the 2027 agenda is curated to spotlight next-generation conjugate design, strategies to overcome resistance mechanisms, and the latest innovations accelerating ADCs towards clinical validation and earlier lines of treatment.

Description supplied by the event organiser.